7 results match your criteria: "Dallas Allergy and Asthma Center[Affiliation]"
Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review.
J Allergy Clin Immunol
July 2024
Dermavant Sciences, Inc, Morrisville, NC. Electronic address:
Article Synopsis
- The aryl hydrocarbon receptor (AhR) is a transcription factor involved in inflammation and homeostasis, responding to various endogenous and environmental ligands.
- AhR's widespread expression and regulatory capabilities position it as a promising target for therapies, particularly in treating inflammatory skin conditions like psoriasis and atopic dermatitis.
- Tapinarof cream, a nonsteroidal topical AhR agonist, has shown significant efficacy in clinical trials and suggests potential use in other inflammatory diseases due to shared pathogenetic traits.
Curcumin does not significantly affect immediate skin tests.
Allergy Asthma Proc
November 2022
Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, Colorado; and.
Curcumin has been shown to decrease allergic symptoms and biomarkers in some animal and human studies. Our study aimed to determine if curcumin affects immediate skin-prick testing. We enrolled 34 participants sensitized to select antigens.
View Article and Find Full Text PDFOcular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis.
Ann Allergy Asthma Immunol
June 2020
Consumer Healthcare, Medical Department, Sanofi, São Paulo, Brazil.
Background: Allergic rhinitis is a prevalent disease, which can be classed as seasonal (SAR) or perennial. In addition to nasal symptoms, up to 75% of sufferers experience itching, redness, and tearing of the eyes. Intranasal corticosteroids are effective in controlling the allergic nasal symptoms, and increasing evidence suggests that they also can relieve some of the allergic ocular symptoms.
View Article and Find Full Text PDFPatient satisfaction with beclomethasone dipropionate nasal aerosol device with integrated dose counter during daily use.
Allergy Asthma Proc
July 2014
Dallas Allergy and Asthma Center, Dallas, Texas, USA.
Some patients with allergic rhinitis (AR) may prefer a "dry" intranasal corticosteroid aerosol to avoid certain sensory perceptions such as the "wet feeling in the nose" and the "dripping down the throat" associated with aqueous nasal sprays. A nonaqueous hydrofluoroalkane-propelled beclomethasone dipropionate (BDP) nasal aerosol with an established efficacy and safety profile was approved to treat the nasal symptoms associated with AR in adult and adolescent patients. This study was designed to evaluate ease of use and patient satisfaction with the BDP nasal aerosol device in patients with perennial AR (PAR).
View Article and Find Full Text PDFCPT coding for the allergist.
J Allergy Clin Immunol
February 2006
Dallas Allergy and Asthma Center, TX 75231, USA.
Objective: The improved lung deposition of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) extrafine aerosol compared with chlorofluorocarbon beclomethasone dipropionate (CFC-BDP) suggests that lower doses of HFA-BDP may be required to provide equivalent asthma control. The present study was undertaken to test this hypothesis.
Design: A 10- to 12-day run-in period confirmed that patients met established criteria of at least moderate asthma and the asthma was inadequately controlled by current therapy (inhaled beta-agonist and CFC-BDP [< or = 400 microg/d]).